Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3473973 | 0.78 | RXRA (0.59) | PTGS2PTGS1PDPK1 | |
| SCHEMBL19205691 | 0.75 | PTGS2 (0.74) | PTGS2PTGS1KMT2APDPK1 | |
| SCHEMBL3474436 | 0.74 | PTGS2 (0.54) | PTGS2PTGS1PDPK1 | |
| SCHEMBL5858032 | 0.73 | PTGS2 (0.70) | PTGS2PTGS1KMT2AMEN1PDPK1 | |
| SCHEMBL18449128 | 0.71 | PTGS2 (0.71) | PTGS2PTGS1KMT2APDPK1 | |
| SCHEMBL3244766 | 0.71 | PTGS2 (1.00) | PTGS2PTGS1PDPK1 | |
| SCHEMBL3473709 | 0.71 | KMT2A (0.61) | PTGS2KMT2AMEN1FABP3SNCA | |
| SCHEMBL27716914 | 0.71 | KMT2A (0.52) | PTGS2PTGS1KMT2AMEN1MMP2 | |
| SCHEMBL3472391 | 0.69 | RXRA (0.51) | PTGS2PTGS1 | |
| SCHEMBL8904051 | 0.68 | PTGS2 (0.69) | PTGS2PTGS1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| CN-101248048-B | Imidazole based LXR modulators | EXELIXIS INC | 2013-08-28 | — | — | CN | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| CN-101248048-A | Imidazole based LXR modulators | EXELIXIS INC (US) | 2008-08-20 | — | — | CN | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | PTGS2 1500/4885PTGS1 803/4885KMT2A 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.